Therapeutic Advances in Adult B-cell Acute Lymphoblastic Leukemia with KMT2A Rearrangements

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• KMT2A rearrangements define a high-risk adult B-cell acute lymphoblastic leukemia (B-ALL) subtype.
• Conventional chemotherapy and stem cell transplantation offer suboptimal outcomes for KMT2Ar B-ALL.
• Novel therapeutic strategies are urgently needed to improve survival rates.

Purpose of the Study:

• To provide a comprehensive review of current and emerging treatments for adult KMT2Ar B-ALL.
• To summarize clinical evidence for immunotherapies and targeted molecular agents.
• To highlight challenges and future directions in KMT2Ar B-ALL therapy.

Main Methods:

• Literature review of clinical trials and preclinical studies.
• Analysis of outcomes for chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT), antibody-based immunotherapy, cellular immunotherapy, and small molecular inhibitors.
• Discussion of resistance mechanisms and emerging therapeutic targets.

Main Results:

• Pediatric-inspired chemotherapy and allo-HSCT show limited efficacy.
• Antibody-based immunotherapies (blinatumomab, inotuzumab ozogamicin) demonstrate clinical activity.
• CD19-directed CAR T-cell therapy and menin inhibitors show promise but face resistance.
• Other molecular approaches are under investigation.

Conclusions:

• Significant progress has been made with novel agents, but treatment resistance and relapse remain critical issues.
• Further research into combination strategies is essential for improving outcomes in adult KMT2Ar B-ALL.
• Multi-center, prospective trials are needed to evaluate novel therapeutic combinations.